COC’s application for decreasing cardiovascular risks
https://doi.org/10.21518/2079-701X-2019-6-126-128
Abstract
Nowadays application of combined oral contraceptives with folates is considered not only as effective contraception, but also as treatment of hyperandrogenic dermopathy and prophylaxis of cardiovascular diseases.
About the Authors
L. Yu. Karakhalis
Federal State Budgetary Educational Institution of Higher Education «Kuban State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Karakhalis Lyudmila Yuryevna – Dr. of Sci. (Med.), Professor of Chair of Obstetrics, Gynecology and Perinatology, Faculty of Advanced Training and Professional Retraining of Specialists
350063, Krasnodar, Mitrofana Sedina St., 4
G. A. Penzhoyan
Federal State Budgetary Educational Institution of Higher Education «Kuban State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Penzhoyan Grigory Artemovich – Dr. of Sci. (Med.), Professor, Head of Chair of Obstetrics, Gynecology and Perinatology, Faculty of Advanced Training and Professional Retraining of Specialists
350063, Krasnodar, Mitrofana Sedina St., 4
M. N. Karakhalis
Federal State Budgetary Educational Institution of Higher Education «Kuban State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Karakhalis Mark Nikolaevich – 6th year student, General Medicine Faculty of Advanced Training and Professional Retraining of Specialists
350063, Krasnodar, Mitrofana Sedina St., 4
References
1. Barry J.A. Azizia M.M., Hardiman P.J. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748-58. doi: 10.1093/humupd/dmu012.
2. Nalliah S., Ganesalingam M., Jegasothy R. Simultaneous Presence of Pelvic Endometriosis and Polycystic Ovary Syndrome. leJSME. 2008;2(2):27-29.
3. Scicchitano P., Dentamaro I., Carbonara R., Bulzis G., Dachille A., Caputo P., et al. Cardiovascular Risk in Women With PCOS. Int J Endocrinol Metab. 2012;10(4):611-8. doi: 10.5812/ijem.4020.
4. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149-55.
5. Yarali H., Yildirir A., Aybar F., Kabakci G., Bukulmez O., Akgul E., et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril. 2001;76(3):511-6.
6. Schachter M., Raziel A., Friedler S., Strassburger D., Bern O., Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod. 2003;18(4):721-7.
7. Loverro G., Lorusso F., Mei L., Depalo R., Cormio G., Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest. 2002;53(3):157-62.
8. Kao Y.H., Chiu W.C., Hsu M.I., Chen Y.J. Endothelial progenitor cell dysfunction in polycystic ovary syndrome: implications for the genesis of cardiovascular diseases. Int J Fertil Steril. 2013;6(4):208-213.
9. Abbott D.H., Levine J.E., Dumesic D.A. Translation insight into polycystic ovary syndrome (PCOS) from female monkeys with PCOS-like traits. Curr Pharm Des. 2016;22(3):5625-5633.
10. Asik M., Altinbas K., Eroglu M., Karaahmet E., Erbag G., Ertekin H., Sen H. Evaluation of affective temperament and anxiety-depression levels of patients with polycystic ovary syndrome. J Affect Disord. 2015;185:214-218.
11. Azziz R., Carmina E., Chen Z., Dunaif A., Laven J.S., Legro R.S., Lizneva D., Natterson-Horowtiz B., Teede H.J., Yildiz B.O. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
12. Bozdag G., Mutusoglu S., Zengin D., Karabulut E., Yildiz B.O. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-2855. doi: 10.1093/humrep/dew218.
13. Yildiz B.O. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:794-802.
14. Karakhalis L.Yu., Ponomarev V.V., Bezrukov A.G., Penzhoyan G.A., Donchenko E.A. Management of patients with polycystic ovary syndrome in intergenetic interval. Problemy Reproduktsii. 2017;5:61-64. (In Russ).
15. Karakhalis L.Yu, Fedorovich O.K. Differencirovannoe primenenie kombinirovannykh peroral’nykh kontraceptivov. Akuscherstvo i Ginekologia. 2006;6:51-53. (In Russ.).
16. Khalafyan A.A. Statistica 6. Matematichaskaya statistika s ehlementami teorii veroyatnostejj. Uchebnik. M.: BINOM. 2010;496. (In Russ.).
Review
For citations:
Karakhalis LY, Penzhoyan GA, Karakhalis MN. COC’s application for decreasing cardiovascular risks. Meditsinskiy sovet = Medical Council. 2019;(6):126-128. (In Russ.) https://doi.org/10.21518/2079-701X-2019-6-126-128
Views:
742
Email this article 